Co-Authors
This is a "connection" page, showing publications co-authored by LEI HUO and WILLIAM F SYMMANS.
Connection Strength
1.375
-
PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
Score: 0.228
-
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
Score: 0.226
-
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
Score: 0.207
-
Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol. 2018 07; 77:121-129.
Score: 0.158
-
MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol. 2016 Apr; 29(4):330-46.
Score: 0.136
-
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
Score: 0.060
-
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469.
Score: 0.056
-
Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
Score: 0.056
-
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. NPJ Breast Cancer. 2023 Jan 10; 9(1):2.
Score: 0.055
-
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375.
Score: 0.050
-
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs. 2021 04; 39(2):509-515.
Score: 0.047
-
Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174.
Score: 0.042
-
Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11.
Score: 0.030
-
Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med. 2010 Feb; 134(2):162-3; author reply 163.
Score: 0.022